Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

ABC News chief medical correspondent Dr. Tara Narula breaks down what to know about a new study that says Zepbound may be ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Zepbound won on all measures of effectiveness in a trial presented Monday at an obesity conference, spurring an average of 47% more weight loss over 72 weeks. Lilly, which funded the research ...